Effects of loratadine (SCH 29851) in suppression of histamine-induced skin wheals.
The efficacy and safety of single oral doses (10, 20, 40, and 80 mg) of loratadine (SCH 29851) in suppressing formation of histamine-induced wheals were assessed in a crossover study in 29 healthy male subjects. One hour prior to dosing and 1, 2, 3, 4, 6, 8, 12, 16, 24, 28, 32, 36, 40, and 48 hours after dosing, histamine and saline were injected intradermally into opposite arms. Measurements of resulting wheal areas showed loratadine suppressed wheal formation significantly better than placebo; suppression was dose related. The mean suppression over 48 hours was 16% in placebo-treated subjects and 35%, 45%, 51%, and 67% in the 10, 20, 40, and 80 mg loratadine-treated subjects, respectively. The onset of action occurred within the first hour. Duration of suppression was dose related, ranging from 12 hours with the lowest dose (10 mg) to 48 hours with the higher doses (40 and 80 mg). Incidence of sedation and other side effects were comparable among all doses of loratadine and placebo.
Kassem
N
N
Pharmaceutical Research Division, Schering-Plough Corporation, Kenilworth, New Jersey.
Roman
I
I
Gural
R
R
Dyer
J G
JG
Robillard
N
N
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D003533:Cyproheptadine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006632:Histamine; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D017336:Loratadine; D008297:Male; D014581:Urticaria / Q000139:chemically induced / Q000188:drug therapy*
D006993:Hypnotics and Sedatives; D003533:Cyproheptadine; D017336:Loratadine; D006632:Histamine